Researchers have uncovered a new way to attack lymphoma by targeting a non-catalytic region of a key regulatory enzyme, rather than its traditional active site. Researchers at VCU Massey Comprehensive ...
“Many confounding factors in real life—including lifestyle, UV exposure, occupational hazards, and immune status—can ...
Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...
A novel dual biologic regimen combining dazodalibep and belatacept is well tolerated and could enable more than half the kidney transplant recipients to avoid broader metabolic pathway inhibitors.
Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...
Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as a ...
Immunotherapy has transformed the field of medicine. In the context of cancer, immune cells become dysregulated and lose the ...
We are now approaching six years since COVID-19 was declared a pandemic by the World Health Organization, yet talk of vaccines and our immune systems persists in our cultural conversations — from ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results